GLP-1 receptor agonists reduce HF worsening events in HFpEF but show no benefit in HFrEF
GLP-1 drugs help heart failure with preserved ejection fraction
This meta-analysis of 11,234 patients with heart failure (HFpEF and HFrEF) found that GLP-1 receptor agonists significantly reduced HF worse…
GLP-1 receptor agonists improve outcomes in heart failure with preserved ejection fraction but not in reduced ejection fraction, according t…
Vagal nerve stimulation did not meet the primary endpoint of reduced cardiovascular death or HF hospitalization
Trial shows vagal nerve stimulation for heart failure patients
This randomized controlled trial evaluated vagal nerve stimulation (VNS) in 532 patients with heart failure and reduced ejection fraction. T…
A new trial explores if stimulating a specific nerve can help people living with heart failure manage their symptoms and stay out of the hos…
SGLT2 inhibitors provide robust prognostic benefits in heart failure with inconsistent results in post-myocardial infarction settings
SGLT2 inhibitors show promise for heart failure and diabetes
This narrative review examines the cardiovascular and metabolic effects of SGLT2 inhibitors, specifically empagliflozin and dapagliflozin. T…
New evidence shows how SGLT2 inhibitors may protect the heart and manage risks for patients with type 2 diabetes and heart failure.
Systematic review suggests modest risk reduction with SGLT2 inhibitors or ARNIs added to standard therapy in severe heart failure
Moderate evidence supports adding SGLT2 inhibitors to heart failure treatment
This systematic review and network meta-analysis evaluated adding SGLT2 inhibitors or angiotensin receptor-neprilysin inhibitors to neurohor…
A large analysis suggests adding SGLT2 inhibitors may lower risk of death or hospitalization for heart failure, though caution is advised.
Network meta-analysis compares glucose-lowering therapies for heart failure with reduced ejection fraction and type 2 diabetes
Sotagliflozin Cuts Heart Failure Risk By Half In High-Risk Patients
This systematic review and network meta-analysis synthesized evidence on three glucose-lowering therapies for patients with coexisting heart…
New drugs for diabetes could also save lives in people with heart failure and lower the need for hospital visits.
Higher LDH levels linked to increased heart failure events in HFrEF patients
A Simple Blood Test Could Predict Heart Failure Worsening
This analysis of the Phase 3 GALACTIC-HF trial examined lactate dehydrogenase (LDH) levels in 8,179 patients with heart failure with reduced…
A widely available blood test for cell damage may help doctors spot which heart failure patients face the highest risk of hospitalization or…
Omecamtiv mecarbil shows trend toward reduced serious arrhythmia risk in HFrEF post hoc analysis
Heart Drug Shows Promise Against Deadly Heart Rhythms
This post hoc analysis of a randomized controlled trial evaluated omecamtiv mecarbil versus placebo in 8232 participants with symptomatic ch…
A heart failure medication already shown to improve pumping strength may also protect against sudden cardiac arrest, especially in patients …
Qiliqiangxin reduces cardiovascular events in heart failure with reduced ejection fraction across LVEF subgroups
Lower heart function gets worse care but this drug helps everyone equally
This post hoc analysis of a Phase 3 RCT in 3110 patients with symptomatic HFrEF found that adding qiliqiangxin to guideline-directed therapy…
This heart drug works for patients with weak hearts just as well as it does for those with slightly stronger pumps
Meta-analysis finds Cimlanod does not reduce mortality in HFrEF, increases hypotension risk
Cimlanod did not reduce death in heart failure patients
This meta-analysis of 459 patients with HFrEF found that Cimlanod did not significantly reduce all-cause or cardiac mortality compared to pl…
A meta-analysis of heart failure patients found Cimlanod did not lower death risk and increased the chance of low blood pressure symptoms.
Vericiguat showed no significant effect on flow-mediated dilation in a small pilot trial of 26 heart failure patients
Pilot trial shows vericiguat may lower heart failure blood pressure markers
This pilot, randomized, double-blind, placebo-controlled trial enrolled 26 patients with heart failure with reduced ejection fraction (HFrEF…
A small pilot trial found vericiguat reduced a heart failure blood pressure marker, though the study was too small to confirm this benefit.
Higher Lactate Dehydrogenase-to-Albumin Ratio Associated With Increased Readmissions and Mortality in Heart Failure
High Blood Marker Tied to Worse Heart Failure Outcomes
This retrospective cohort study included 1,084 hospitalized patients with heart failure with reduced or mildly reduced ejection fraction.
A new blood marker combo can spot heart failure patients most likely to get worse — helping doctors act sooner.
Observational study reveals 'tug-of-war' contraction patterns in healthy and infarcted hearts
New research reveals a hidden heart tug-of-war that causes failure
This observational study describes mesoscale contraction patterns in healthy individuals and patients with myocardial infarction.
A hidden tug-of-war inside your heart explains why some pumps fail while others keep going strong during stress.
Research across Heart Failure
Related studies from across the Heart Failure family.
Higher serum total bilirubin levels associated with lower long-term risk in coronary heart disease patients
High bilirubin levels linked to lower heart risk in some cases
This meta-analysis examined the association between serum total bilirubin and major adverse cardiovascular events in patients undergoing per…
New data suggests high bilirubin might protect patients with coronary heart disease from long-term risks, though the evidence is still early…
GLP-1 receptor agonists and tirzepatide provide cardiovascular benefits across multiple clinical scenarios
Incretin Drugs Show Heart Benefits Across Multiple Conditions
This state-of-the-art review synthesizes evidence regarding incretin analogues, specifically GLP-1 receptor agonists and tirzepatide. The re…
GLP-1 drugs and tirzepatide prove heart benefits in diabetes, obesity, heart failure, and more.
Targeting protein acylation modifications via SIRT1 and HDACs may mitigate myocardial injury and inflammation
New ways to treat heart failure through protein modifications
This narrative review explores how protein acylation modifications, including acetylation and lactylation, regulate metabolic signaling in c…
Scientists identify how targeting specific protein changes can help repair heart tissue and reduce inflammation in patients with heart disea…
Percutaneous transcatheter closure using an Amplatzer Muscular VSD Occluder treats left ventricular pseudoaneurysm
Transcatheter Closure Shows Promise for Heart Failure Patients
This case report describes a 75-year-old male with heart failure and a left ventricular pseudoaneurysm successfully treated via percutaneous…
A new procedure using a transcatheter occluder may offer a safe way to treat heart failure caused by a specific heart wall defect.
Remote cardiac rehabilitation supported by mHealth improves exercise capacity in patients with heart failure
Virtual cardiac rehab improves exercise capacity for heart failure patients
Researchers evaluated the impact of structured, remote, and hybrid cardiac rehabilitation programs compared to usual care or center-based mo…
Remote and hybrid heart rehabilitation programs using mobile health tools can improve walking distance and oxygen use in people with heart f…
Neural-immune-cardiovascular axis emerges as therapeutic target in atherosclerosis, hypertension, heart failure
New pathways link nerves and immunity in heart disease
This systematic review synthesizes evidence on the neural-immune-cardiovascular axis in cardiovascular homeostasis and pathogenesis. It exam…
Scientists are mapping how the connection between your nervous system and immune cells may drive conditions like high blood pressure and hea…
Cognitive impairment affects 39% of chronic heart failure patients in pooled analysis
Heart Failure Patients Face High Risk of Cognitive Impairment
This meta-analysis of 14 studies (5,127 patients) reports a pooled cognitive impairment prevalence of 39.3% in chronic heart failure. Risk f…
Nearly 40% of people with chronic heart failure experience cognitive impairment, with specific factors like age and depression increasing th…
Unified cardiometabolic disease framework links T2DM, ASCVD, HFpEF, MASLD, hypertension, and CKD via shared pathophysiology
New Framework Links Heart and Kidney Health in Diabetes
This guideline provides a narrative review of the unified cardiometabolic disease (UCD) continuum. It argues that conditions like T2DM, ASCV…
Experts suggest that diabetes, heart failure, and kidney disease may share a single underlying cause rather than being separate conditions.
Persistent insomnia in heart failure is associated with higher anxiety and lower functional capacity
Persistent insomnia linked to higher anxiety in heart failure patients
This secondary analysis of a randomized trial involving 400 patients with heart failure identified distinct insomnia trajectories over 12 mo…
A new look at heart failure data shows that lasting sleep issues are tied to higher anxiety and lower physical ability.
MAGGIC Score Predicts Mortality Outcomes in Patients Undergoing Mitral Valve Transcatheter Edge to Edge Repair
New scoring system helps predict heart failure surgery risks
The MAGGIC score demonstrates significant predictive value for mortality in patients with functional or degenerative mitral regurgitation af…
A new risk score accurately predicts death rates for patients undergoing specific heart valve repairs, outperforming several standard models…
Patients with cardiovascular diseases show measurable prevalence of active cancer across multiple conditions
Heart disease patients show measurable risk of developing various cancers
This systematic review and meta-analysis analyzed 4,759,695 patients to determine the prevalence of active cancer in individuals with variou…
New data shows that people with heart conditions like stroke or heart failure have a measurable rate of active cancer cases.
Macrophage migration inhibitory factor serves as a potential biomarker and therapeutic target for atrial fibrillation
Protein levels may predict heart failure and stroke risks
This systematic review synthesizes evidence regarding macrophage migration inhibitory factor (MIF) in the context of atrial fibrillation and…
A specific protein called MIF is linked to heart damage and can help doctors predict serious complications like stroke or heart failure.
Questions about Heart Failure with Reduced Ejection Fraction
Does adding qiliqiangxin to my current treatment help my heart failure with reduced ejection fraction?
Yes, adding qiliqiangxin to your current treatment may reduce cardiovascular death and heart failure hospitalization in HFrEF, based on a large trial and meta-analysis.
Full answer →Will taking Cimlanod cause low blood pressure in patients with heart failure with reduced ejection fraction?
Yes, Cimlanod significantly increases the risk of low blood pressure (hypotension) in patients with heart failure with reduced ejection fraction, according to a meta-analysis.
Full answer →Does Cimlanod lower the chance of dying from heart failure with reduced ejection fraction?
No, Cimlanod does not significantly lower the chance of dying from heart failure with reduced ejection fraction based on current evidence.
Full answer →All Heart Failure with Reduced Ejection Fraction Articles
- GLP-1 receptor agonists reduce HF worsening events in HFpEF but show no benefit in HFrEF
- Vagal nerve stimulation did not meet the primary endpoint of reduced cardiovascular death or HF hospitalization
- SGLT2 inhibitors provide robust prognostic benefits in heart failure with inconsistent results in post-myocardial infarction settings
- Systematic review suggests modest risk reduction with SGLT2 inhibitors or ARNIs added to standard therapy in severe heart failure
- Network meta-analysis compares glucose-lowering therapies for heart failure with reduced ejection fraction and type 2 diabetes
- Higher LDH levels linked to increased heart failure events in HFrEF patients
- Qiliqiangxin reduces cardiovascular events in heart failure with reduced ejection fraction across LVEF subgroups
- Omecamtiv mecarbil shows trend toward reduced serious arrhythmia risk in HFrEF post hoc analysis
- Vericiguat showed no significant effect on flow-mediated dilation in a small pilot trial of 26 heart failure patients
- Meta-analysis finds Cimlanod does not reduce mortality in HFrEF, increases hypotension risk
- Higher Lactate Dehydrogenase-to-Albumin Ratio Associated With Increased Readmissions and Mortality in Heart Failure
- Observational study reveals 'tug-of-war' contraction patterns in healthy and infarcted hearts
- GLP-1 receptor agonists associated with lower mortality in HFrEF on GDMT
- Qiliqiangxin capsule adjunctive therapy reduces cardiovascular death and hospitalization in patients with heart failure with reduced ejection fraction
- Remote monitoring chatbot increased GDMT target dose achievement in recently discharged HFrEF patients compared to standard care